{"id":1528,"date":"2020-02-08T16:53:38","date_gmt":"2020-02-08T15:53:38","guid":{"rendered":"http:\/\/invivo.partners\/portoflio_invivo\/onechain-immunotherapeutics\/"},"modified":"2024-03-05T12:22:55","modified_gmt":"2024-03-05T11:22:55","slug":"onechain-immunotherapeutics","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/","title":{"rendered":"OneChain Immunotherapeutics"},"content":{"rendered":"\r\n<p class=\"wp-block-paragraph\">OneChain Immunotherapeutics es una empresa <em>spin-off<\/em> del <strong>Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras<\/strong> <strong>(IJC)<\/strong> e <strong>ICREA. <\/strong>El objetivo de la empresa es desarrollar inmunoterapias contra las neoplasias hematol\u00f3gicas utilizando <strong>terapias con<\/strong> <strong>c\u00e9lulas T Gamma Delta<\/strong> y generar nuevos candidatos <strong>CAR-T<\/strong> contra diferentes ant\u00edgenos. El primer candidato es un CAR-CD1a para la co-T-ALL. El objetivo de la empresa es desarrollar terapias <strong>CAR-T <\/strong>utilizando una <strong>plataforma alog\u00e9nica<\/strong> basada en un m\u00e9todo novedoso y eficiente para la generaci\u00f3n selectiva de <strong>c\u00e9lulas V\u03b41+ T<\/strong> citot\u00f3xicas humanas.<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>CEO: Stefanos Theoharis<\/li>\r\n<li>CSO y Fundador: Pablo Men\u00e9ndez<\/li>\r\n<li>Ubicaci\u00f3n: Barcelona<\/li>\r\n<li>P\u00e1gina web: <a href=\"http:\/\/onechaintx.com\" target=\"_blank\" rel=\"noreferrer noopener\">onechaintx.com<\/a><\/li>\r\n<\/ul>\r\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[507],"class_list":["post-1528","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-invivoventures"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OneChain Immunotherapeutics - Invivo Partners<\/title>\n<meta name=\"description\" content=\"OneChain Immunotherapeutics es una empresa spin-off del Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras e ICREA, que tiene como objetivo desarrollar candidatos CAR-T contra diferentes ant\u00edgenos como tratamiento para neoplasias hematol\u00f3gicas, bas\u00e1ndose en la investigaci\u00f3n del Dr. Pablo Men\u00e9ndez.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OneChain Immunotherapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"OneChain Immunotherapeutics es una empresa spin-off del Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras e ICREA, que tiene como objetivo desarrollar candidatos CAR-T contra diferentes ant\u00edgenos como tratamiento para neoplasias hematol\u00f3gicas, bas\u00e1ndose en la investigaci\u00f3n del Dr. Pablo Men\u00e9ndez.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-05T11:22:55+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/\",\"url\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/\",\"name\":\"OneChain Immunotherapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-02-08T15:53:38+00:00\",\"dateModified\":\"2024-03-05T11:22:55+00:00\",\"description\":\"OneChain Immunotherapeutics es una empresa spin-off del Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras e ICREA, que tiene como objetivo desarrollar candidatos CAR-T contra diferentes ant\u00edgenos como tratamiento para neoplasias hematol\u00f3gicas, bas\u00e1ndose en la investigaci\u00f3n del Dr. Pablo Men\u00e9ndez.\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OneChain Immunotherapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OneChain Immunotherapeutics - Invivo Partners","description":"OneChain Immunotherapeutics es una empresa spin-off del Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras e ICREA, que tiene como objetivo desarrollar candidatos CAR-T contra diferentes ant\u00edgenos como tratamiento para neoplasias hematol\u00f3gicas, bas\u00e1ndose en la investigaci\u00f3n del Dr. Pablo Men\u00e9ndez.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/","og_locale":"es_ES","og_type":"article","og_title":"OneChain Immunotherapeutics - Invivo Partners","og_description":"OneChain Immunotherapeutics es una empresa spin-off del Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras e ICREA, que tiene como objetivo desarrollar candidatos CAR-T contra diferentes ant\u00edgenos como tratamiento para neoplasias hematol\u00f3gicas, bas\u00e1ndose en la investigaci\u00f3n del Dr. Pablo Men\u00e9ndez.","og_url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/","og_site_name":"Invivo Partners","article_modified_time":"2024-03-05T11:22:55+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/","url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/","name":"OneChain Immunotherapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-02-08T15:53:38+00:00","dateModified":"2024-03-05T11:22:55+00:00","description":"OneChain Immunotherapeutics es una empresa spin-off del Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras e ICREA, que tiene como objetivo desarrollar candidatos CAR-T contra diferentes ant\u00edgenos como tratamiento para neoplasias hematol\u00f3gicas, bas\u00e1ndose en la investigaci\u00f3n del Dr. Pablo Men\u00e9ndez.","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"OneChain Immunotherapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo\/1528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=1528"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tipo_portfolio?post=1528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}